Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc
6-sulfo LacNAc+ monocytes
CD8+ T cells
plasmacytoid dendritic cells
radiochemotherapy
rectal cancer
tumor immune architecture
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
28
08
2018
accepted:
06
03
2019
entrez:
16
4
2019
pubmed:
16
4
2019
medline:
5
8
2020
Statut:
epublish
Résumé
Neoadjuvant radiochemotherapy (nRCT) can significantly influence the tumor immune architecture that plays a pivotal role in regulating tumor growth. Whereas, various studies have investigated the effect of nRCT on tumor-infiltrating T cells, little is known about its impact on the frequency and activation status of human dendritic cells (DCs). Plasmacytoid DCs (pDCs) essentially contribute to the regulation of innate and adaptive immunity and may profoundly influence tumor progression. Recent studies have revealed that higher pDC numbers are associated with poor prognosis in cancer patients. 6-sulfo LacNAc-expressing monocytes (slanMo) represent a particular proinflammatory subset of human non-classical blood monocytes that can differentiate into DCs. Recently, we have reported that activated slanMo produce various proinflammatory cytokines and efficiently stimulate natural killer cells and T lymphocytes. slanMo were also shown to accumulate in clear cell renal cell carcinoma (ccRCC) and in metastatic lymph nodes from cancer patients. Here, we investigated the influence of nRCT on the frequency of rectal cancer-infiltrating pDCs and slanMo. When evaluating rectal cancer tissues obtained from patients after nRCT, a significantly higher density of pDCs in comparison to pre-nRCT tissue samples was found. In contrast, the density of slanMo was not significantly altered by nRCT. Further studies revealed that nRCT significantly enhances the proportion of rectal cancer-infiltrating CD8
Identifiants
pubmed: 30984181
doi: 10.3389/fimmu.2019.00602
pmc: PMC6450462
doi:
Substances chimiques
6-sulfo-LacNac
0
Amino Sugars
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
602Références
J Immunother. 2001 Mar-Apr;24(2):130-7
pubmed: 11265770
J Exp Med. 2001 Dec 17;194(12):1823-34
pubmed: 11748283
J Pathol. 2002 Jan;196(1):37-43
pubmed: 11748640
Blood. 2002 Aug 15;100(4):1502-4
pubmed: 12149240
Immunity. 2002 Sep;17(3):289-301
pubmed: 12354382
Eur J Immunol. 2003 Apr;33(4):1052-62
pubmed: 12672071
Cancer Res. 2003 Oct 1;63(19):6478-87
pubmed: 14559840
Anticancer Res. 2003 Nov-Dec;23(6a):4423-6
pubmed: 14666729
Cancer Immunol Immunother. 2004 Nov;53(11):978-86
pubmed: 15197496
Clin Cancer Res. 2004 Nov 15;10(22):7466-74
pubmed: 15569976
J Immunol. 2005 Apr 1;174(7):4127-34
pubmed: 15778372
Clin Cancer Res. 2005 Apr 1;11(7):2576-82
pubmed: 15814636
Blood. 2006 May 1;107(9):3617-23
pubmed: 16397134
Immunity. 2006 Jun;24(6):767-77
pubmed: 16782032
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Nat Med. 2007 Jan;13(1):54-61
pubmed: 17187072
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
J Clin Invest. 2007 Sep;117(9):2570-82
pubmed: 17710230
Nature. 2007 Sep 27;449(7161):419-26
pubmed: 17898760
J Transl Med. 2007 Nov 29;5:62
pubmed: 18047662
J Clin Invest. 2008 Mar;118(3):1165-75
pubmed: 18259609
Nat Rev Immunol. 2008 Aug;8(8):594-606
pubmed: 18641647
Int J Cancer. 2009 Jan 15;124(2):358-66
pubmed: 18942710
Cancer Res. 2009 Apr 1;69(7):3077-85
pubmed: 19293190
J Clin Oncol. 2009 Dec 10;27(35):5944-51
pubmed: 19858404
Trends Immunol. 2010 Jul;31(7):270-7
pubmed: 20579936
Cancer Res. 2011 Apr 1;71(7):2488-96
pubmed: 21300764
J Allergy Clin Immunol. 2011 Mar;127(3):787-94.e1-9
pubmed: 21377044
Cancer Res. 2011 Aug 15;71(16):5423-34
pubmed: 21697280
Int J Colorectal Dis. 2012 Feb;27(2):159-69
pubmed: 22065108
Cancer Res. 2012 Oct 15;72(20):5188-97
pubmed: 22836755
Int J Cancer. 2013 Jul;133(1):120-9
pubmed: 23292955
Cancer Res. 2013 Feb 1;73(3):1063-75
pubmed: 23345163
Carcinogenesis. 2013 Mar;34(3):503-12
pubmed: 23354310
J Pathol. 2013 Jul;230(3):241-8
pubmed: 23460481
Blood. 2013 May 2;121(18):3609-18
pubmed: 23460612
Cancer Res. 2013 Aug 1;73(15):4629-40
pubmed: 23722543
Pathol Res Pract. 2013 Dec;209(12):774-8
pubmed: 24080284
Cancer Cell. 2013 Nov 11;24(5):589-602
pubmed: 24209604
Nat Commun. 2014;5:3029
pubmed: 24398631
Ann Surg Oncol. 2014 Jun;21 Suppl 3:S414-21
pubmed: 24566864
Haematologica. 2014 Jun;99(6):e86-9
pubmed: 24682513
Cancer Res. 2014 Nov 1;74(21):6022-35
pubmed: 25209187
Nat Med. 2014 Nov;20(11):1301-9
pubmed: 25344738
Oncotarget. 2015 Feb 20;6(5):2981-91
pubmed: 25671296
Nat Rev Immunol. 2015 Jul;15(7):405-14
pubmed: 26027717
Nat Rev Cancer. 2015 Jul;15(7):409-25
pubmed: 26105538
Oncoimmunology. 2015 Mar 2;4(6):e1008342
pubmed: 26155414
Nat Rev Immunol. 2015 Aug;15(8):471-85
pubmed: 26160613
Transl Res. 2015 Dec;166(6):721-732.e1
pubmed: 26209749
Am J Cancer Res. 2015 May 15;5(6):2064-74
pubmed: 26269765
Nat Med. 2015 Oct;21(10):1209-15
pubmed: 26322579
Cancer Immunol Immunother. 2016 Jul;65(7):779-86
pubmed: 26590829
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Gastroenterol Rep (Oxf). 2016 Aug;4(3):206-9
pubmed: 27412436
Int J Biol Sci. 2016 Jul 17;12(8):1022-31
pubmed: 27489505
Nat Rev Clin Oncol. 2017 Jun;14(6):365-379
pubmed: 28094262
Oncotarget. 2017 Mar 21;8(12):19803-19813
pubmed: 28177891
J Leukoc Biol. 2017 Oct;102(4):1055-1068
pubmed: 28720687
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Cancer. 1989 Feb 1;63(3):496-503
pubmed: 2912528
Oncoimmunology. 2017 Nov 7;7(2):e1393133
pubmed: 29308324
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Cancer Res. 2018 Jul 1;78(13):3544-3559
pubmed: 29748373
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
JCI Insight. 2018 Jun 7;3(11):null
pubmed: 29875315
Oncoimmunology. 2018 Mar 19;7(7):e1444411
pubmed: 29900053
Front Immunol. 2018 Jun 21;9:1352
pubmed: 29977237
Eur J Immunol. 1998 Dec;28(12):4084-93
pubmed: 9862344